WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Wednesday, January 24, 2007

Hide?	Set Name	Query	Hit Count
		DB=PGPB; PLUR=YES; OP=ADJ	
☐	L1	(oxopyridin and azaindol).clm.	1

END OF SEARCH HISTORY

```
* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *
 * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 08:43:22 ON 24 JAN 2007

=> file reg
=>Uploading C:\Program Files\Stnexp\Queries\10826136.str
```



```
chain nodes :
10  11  12  13  14
ring nodes :
1  2  3  4  5  6  7  8  9  15  16  17  18  19  20
chain bonds :
7-11  10-11  11-12  12-13  12-14  14-16
ring bonds :
1-2  1-6  2-3  3-4  4-5  4-7  5-6  5-9  7-8  8-9  15-16  15-20  16-17  17-18  18-19
19-20
exact/norm bonds :
5-9  8-9  10-11  12-13  12-14  14-16
exact bonds :
4-7  7-8  7-11  11-12
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  15-16  15-20  16-17  17-18  18-19  19-20
isolated ring systems :
containing 1 : 15 :


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:CLASS
11:CLASS  12:CLASS  13:CLASS  14:CLASS  15:Atom  16:Atom  17:Atom  18:Atom  19:Atom
20:Atom



L1      STRUCTURE UPLOADED

=> dis l1
L1 HAS NO ANSWERS
L1                STR
```



```
Structure attributes must be viewed using STN Express query preparation.


=> s l1 sam
```

```
L2             2 SEA SSS SAM L1

=> s l1 full
L3            45 SEA SSS FUL L1

=> file caplus

=> s l3
L4             3 L3

=> s l4 and pd<may 2003
      23671395 PD<MAY 2003
                 (PD<20030500)
L5             2 L4 AND PD<MAY 2003

=> dis l5 1-2 bib abs hitstr

L5   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2006:1209981  CAPLUS Full-text
DN   145:505426
TI   Preparation of 7-azaindoles as phosphodiesterase 4 inhibitors for treating
     inflammatory skin diseases and proliferative skin diseases
IN   Hofgen, Norbert; Egerland, Ute; Kronbach, Thomas; Marx, Degenhard;
     Szelenyi, Stefan; Kuss, Hildegard; Polymeropoulos, Emmanuel
PA   Germany
SO   U.S. Pat. Appl. Publ., 15pp., Cont.-in-part of U.S. Ser. No. 399,051.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 2
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
PI   US 2006258700        A1    20061116    US 2006-329400         20060110
     DE 10053275          A1    20020502    DE 2000-10053275       20001027 <--
     WO 2002034747        A1    20020502    WO 2001-EP12376        20011025 <--
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
             PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
             US, UZ, VN, YU, ZA, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     ZA 2003003236        A     20030731    ZA 2003-3236           20030425
     US 2004106641        A1    20040603    US 2003-399051         20030617
PRAI DE 2000-10053275     A     20001027
     US 2000-244342P      P     20001030
     WO 2001-EP12376      W     20011025
     US 2003-399051       A2    20030617
OS   MARPAT 145:505426
GI
```



I

AB The title azaindoles I [n = 1, 2; R1 = (un)substituted alkyl, alkenyl, benzyl, etc.; R2, R3 = H, (un)substituted alkyl, Ph, pyridyl, triazolyl; NR2R3 = morpholino, thiomorpholino, thiomorpholine S,S-dioxide, 4-methylpiperazino] were prepared for use as PDE-4 inhibitors. Thus, 1-cyclopropylmethyl-7-azaindole-3-carboxylic acid was converted to the acid chloride and treated with 4-aminomethylpyridine to give the amide I [n = 1; R1 = cyclopropylmethyl; R2 = 4-pyridylmethyl; R3 = H] which had an IC50 of 0.710 μM/L against PDE 4.

IT 418794-38-4P 418794-40-8P 418794-42-0P
418794-44-2P 418794-46-4P 418794-47-5P
418794-55-5P 418794-57-7P 418794-59-9P
418794-61-3P 418794-63-5P 418794-64-6P
418794-66-8P 418794-68-0P 418794-70-4P
418794-71-5P 418794-73-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 7-azaindoles as phosphodiesterase 4 inhibitors for treating inflammatory skin diseases and proliferative skin diseases)

RN 418794-38-4 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(3-methoxyphenyl)methyl]-α-oxo- (9CI) (CA INDEX NAME)



RN 418794-40-8 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, 1-[(4-fluorophenyl)methyl]-α-oxo-N-4-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 418794-42-0 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-fluorophenyl)methyl]-α-oxo- (9CI) (CA INDEX NAME)



RN 418794-44-2 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, 1-[(4-chlorophenyl)methyl]-α-oxo-N-4-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 418794-46-4 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, 1-[(4-chlorophenyl)methyl]-N-(3,5-dichloro-4-pyridinyl)-α-oxo- (9CI) (CA INDEX NAME)



RN 418794-47-5 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-methoxyphenyl)methyl]-α-oxo- (9CI) (CA INDEX NAME)



RN 418794-55-5 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-methylphenyl)methyl]-α-oxo- (9CI) (CA INDEX NAME)



RN 418794-57-7 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-hydroxyphenyl)methyl]-α-oxo- (9CI) (CA INDEX NAME)



RN 418794-59-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(3-hydroxyphenyl)methyl]-α-oxo- (9CI) (CA INDEX NAME)



RN 418794-61-3 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, 1-(cyclopropylmethyl)-N-(3,5-dichloro-4-pyridinyl)-α-oxo- (9CI) (CA INDEX NAME)



RN 418794-63-5 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-hexyl-α-oxo- (9CI) (CA INDEX NAME)



RN 418794-64-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-(2-methylpropyl)-α-oxo- (9CI) (CA INDEX NAME)



RN 418794-66-8 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-(2-methyl-2-propenyl)-α-oxo- (9CI) (CA INDEX NAME)



RN 418794-68-0 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-(2-methoxyethyl)-α-oxo- (9CI) (CA INDEX NAME)



RN 418794-70-4 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-(1-naphthalenylmethyl)-α-oxo- (9CI) (CA INDEX NAME)



RN 418794-71-5 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-α-oxo-1-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 418794-73-7 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(3,5-dimethyl-4-isoxazolyl)methyl]-α-oxo- (9CI) (CA INDEX NAME)



L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:332190 CAPLUS Full-text

DN 136:340669
TI Novel 7-azaindolecarboxamides as phosphodiesterase 4 inhibitors
IN Hoefgen, Norbert; Egerland, Ute; Kronbach, Thomas; Marx, Degenhard; Szelenyi, Stefan; Kuss, Hildegard; Polymeropoulos, Emmanuel
PA Arzneimittelwerk Dresden Gmbh, Germany
SO PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2002034747	A1	20020502	WO 2001-EP12376	20011025	<--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
	DE 10053275	A1	20020502	DE 2000-10053275	20001027	<--
	CA 2428468	A1	20020502	CA 2001-2428468	20011025	<--
	AU 200221753	A	20020506	AU 2002-21753	20011025	<--
	EP 1330455	A1	20030730	EP 2001-988718	20011025	
	EP 1330455	B1	20050803			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
	EE 200300166	A	20030815	EE 2003-166	20011025	
	BR 2001014903	A	20031014	BR 2001-14903	20011025	
	HU 200303034	A2	20031229	HU 2003-3034	20011025	
	JP 2004512337	T	20040422	JP 2002-537738	20011025	
	NZ 525369	A	20040924	NZ 2001-525369	20011025	
	AT 301121	T	20050815	AT 2001-988718	20011025	
	PT 1330455	T	20051031	PT 2001-988718	20011025	
	RU 2268887	C2	20060127	RU 2003-115621	20011025	
	ES 2246349	T3	20060216	ES 2001-1988718	20011025	
	NO 2003001722	A	20030414	NO 2003-1722	20030414	<--
	BG 107725	A	20040831	BG 2003-107725	20030416	
	IN 2003KN00463	A	20041218	IN 2003-KN463	20030416	
	ZA 2003003236	A	20030731	ZA 2003-3236	20030425	
	HR 2003000427	A1	20030831	HR 2003-427	20030526	
	US 2004106641	A1	20040603	US 2003-399051	20030617	
	HK 1053839	A1	20051028	HK 2003-106201	20030829	
	US 2006258700	A1	20061116	US 2006-329400	20060110	
PRAI	DE 2000-10053275	A	20001027			
	US 2000-244342P	P	20001030			
	WO 2001-EP12376	W	20011025			
	US 2003-399051	A2	20030617			

OS CASREACT 136:340669; MARPAT 136:340669
GI



I

AB 7-Azaindoles I [n = 1, 2; R1 = (un)substituted alkyl, alkenyl; R2, R3 = H, (un)substituted alkyl, Ph, pyridyl, uracilyl, triazolyl; NR2R3 = morpholino, thiomorpholino, thiomorpholine S,S-dioxide, 4-methylpiperazino] were prepared for use as PDE-4 inhibitors. Thus, 1-cyclopropylmethyl-7-azaindole-3-carboxylic acid was converted to the acid chloride and treated with 4-aminomethylpyridine to give the amide which had an IC50 for PDE-4 inhibition of 0.710 μmol./L.

IT 418794-38-4P 418794-40-8P 418794-42-0P
418794-44-2P 418794-46-4P 418794-47-5P
418794-55-5P 418794-57-7P 418794-59-9P
418794-61-3P 418794-63-5P 418794-64-6P
418794-66-8P 418794-73-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel 7-azaindolecarboxamides as phosphodiesterase 4 inhibitors)

RN 418794-38-4 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(3-methoxyphenyl)methyl]-α-oxo- (9CI) (CA INDEX NAME)



RN 418794-40-8 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, 1-[(4-fluorophenyl)methyl]-α-oxo-N-4-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)



x HCl

RN 418794-42-0 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-fluorophenyl)methyl]-α-oxo- (9CI) (CA INDEX NAME)



RN 418794-44-2 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, 1-[(4-chlorophenyl)methyl]-α-oxo-N-4-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 418794-46-4 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, 1-[(4-chlorophenyl)methyl]-N-(3,5-dichloro-4-pyridinyl)-α-oxo- (9CI) (CA INDEX NAME)



RN 418794-47-5 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-

methoxyphenyl)methyl]-α-oxo- (9CI) (CA INDEX NAME)



RN 418794-55-5 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-methylphenyl)methyl]-α-oxo- (9CI) (CA INDEX NAME)



RN 418794-57-7 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-hydroxyphenyl)methyl]-α-oxo- (9CI) (CA INDEX NAME)



RN 418794-59-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(3-hydroxyphenyl)methyl]-α-oxo- (9CI) (CA INDEX NAME)



RN 418794-61-3 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, 1-(cyclopropylmethyl)-N-(3,5-dichloro-4-pyridinyl)-α-oxo- (9CI) (CA INDEX NAME)



RN 418794-63-5 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-hexyl-α-oxo- (9CI) (CA INDEX NAME)



RN 418794-64-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-(2-methylpropyl)-α-oxo- (9CI) (CA INDEX NAME)



RN 418794-66-8 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-(2-methyl-2-propenyl)-α-oxo- (9CI) (CA INDEX NAME)



RN 418794-73-7 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(3,5-dimethyl-4-isoxazolyl)methyl]-α-oxo- (9CI) (CA INDEX NAME)



IT 418794-68-0P 418794-70-4P 418794-71-5P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel 7-azaindolecarboxamides as phosphodiesterase 4 inhibitors)

RN 418794-68-0 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-(2-methoxyethyl)-α-oxo- (9CI) (CA INDEX NAME)



RN 418794-70-4 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-(1-naphthalenylmethyl)-α-oxo- (9CI) (CA INDEX NAME)



RN 418794-71-5 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-α-oxo-1-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s l4 not l5
L6 1 L4 NOT L5

=> dis l6 bib abs

L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:927204 CAPLUS Full-text
DN 141:395538
TI Preparation of 7-azaindolylglyoxylamides as phosphodiesterase IV inhibitors.
IN Hoefgen, Norbert; Kuss, Hildegard; Olbrich, Matthias; Egerland, Ute; Rundfeldt, Chris; Steinike, Karin; Schindler, Rudolf
PA Elbion A.-G., Germany
SO PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004094416	A1	20041104	WO 2004-EP4339	20040423
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10318610	A1	20041111	DE 2003-10318610	20030424
	US 2004224971	A1	20041111	US 2004-826136	20040416
	AU 2004232483	A1	20041104	AU 2004-232483	20040423
	CA 2523063	A1	20041104	CA 2004-2523063	20040423
	EP 1613627	A1	20060111	EP 2004-729102	20040423
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	BR 2004009790	A	20060530	BR 2004-9790	20040423
	CN 1805960	A	20060719	CN 2004-80016650	20040423
	JP 2006524209	T	20061026	JP 2006-505246	20040423
	NO 2005005515	A	20060124	NO 2005-5515	20051122
PRAI	DE 2003-10318610	A	20030424		
	WO 2004-EP4339	W	20040423		

OS MARPAT 141:395538

GI



I

AB Title compds. [I; A = N, N-oxide group; B = C, N, N-oxide group; R1 = (substituted) alkyl, alkenyl; R2 = H, alkyl; R3, R4 = H, alkyl, OH, SH, NH2, NO2, cyano, SO3H, CO2H, alkoxycarbonyl, halo, alkoxy, alkylthio, (substituted) Ph, pyridyl, etc.], were prepared Thus, N-(3,5- dichloropyridin-4-yl) [1-(4-fluorobenzyl)-7-azaindol-3-yl]glyoxylic acid amide in CH2Cl2 was treated dropwise with m-chloroperbenzoic acid in HOAc followed by stirring for 7 days to give 9.4% N-(3,5-dichloropyridin-4-yl) [1-(4-fluorobenzyl)-7-oxo-7-azaindol-3-yl]glyoxylic acid amide. I inhibited phosphodiesterase 4 with IC50's in the range of 10-10 M to 10-5 M.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	15.85	188.16

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION

CA SUBSCRIBER PRICE -2.34 -2.34

STN INTERNATIONAL LOGOFF AT 08:44:53 ON 24 JAN 2007